Comparative in vitro studies of Tiazofurin and a selenazole analog.
2-beta-D-Ribofuranosylselenazole-4-carboxamide, a selenazole analog of the antitumor agent Tiazofurin, is severalfold more cytotoxic to murine tumor cells in culture than Tiazofurin. Like Tiazofurin, the cytotoxicity of the selenazole analog is reversed by exogenous guanosine, and both nucleosides specifically inhibit IMP dehydrogenase activity in cultured P388 cells. The dose-dependency for this inhibition correlates with the relative cytotoxicities of both drugs, indicating that a more potent inhibition of IMP dehydrogenase by the selenazole analog is primarily responsible for its increased cytotoxicity. The specific inhibition of the isolated enzyme by potential metabolites of the selenazole analog is discussed.
D000818:Animals; D000970:Antineoplastic Agents; D002470:Cell Survival / Q000187:drug effects; D007168:IMP Dehydrogenase / Q000378:metabolism; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000201:enzymology; D007941:Leukemia P388 / Q000188:drug therapy* / Q000201:enzymology; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D009701:Nucleoside-Diphosphate Kinase / Q000037:antagonists & inhibitors; D016566:Organoselenium Compounds; D012254:Ribavirin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012263:Ribonucleosides / Q000627:therapeutic use*; D012643:Selenium / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D016566:Organoselenium Compounds; D012263:Ribonucleosides; D012254:Ribavirin; D007168:IMP Dehydrogenase; D009701:Nucleoside-Diphosphate Kinase; D012643:Selenium; C039064:selenazofurin; C033706:tiazofurin